Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Revive Therapeutics Ltd (RVVTF)

Revive Therapeutics Ltd (RVVTF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RVVTF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1602 +114.92%
on 05/12/22
0.3550 -3.01%
on 05/26/22
+0.0543 (+18.72%)
since 04/26/22
3-Month
0.1200 +186.92%
on 04/06/22
0.3550 -3.01%
on 05/26/22
+0.1354 (+64.82%)
since 02/25/22
52-Week
0.1200 +186.92%
on 04/06/22
0.5100 -32.49%
on 07/07/21
-0.0557 (-13.93%)
since 05/26/21

Most Recent Stories

More News
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Top COVID-19 Treatment Stocks Investors Should Consider

The coronavirus isn’t gone just yet. China just imposed new lockdowns in Shanghai, as the city records some of its highest numbers of new COVID-19 cases. Italy just reported another 30,710 cases on...

PFE : 53.99 (+0.52%)
MRNA : 135.80 (+3.78%)
JNJ : 179.46 (-0.09%)
MRK : 92.31 (-1.54%)
RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Expected to seek DSMB approval to proceed with EUA application to the FDA in Q2-2022 Ongoing regulatory package activities for submission to international...

RVV.CN : 0.440 (+17.33%)
RVVTF : 0.3443 (+21.06%)
Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to date in Turkey TORONTO, Feb. 14, 2022 (GLOBE...

RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
Psilocybin and MDMA Get the Green Light for Medical Use in Canada

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – January 19, 2022 –  After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp...

MMED.NE : 1.020 (+2.00%)
NUMI.TO : 0.3800 (-2.56%)
NUMIF : 0.2940 (-0.84%)
CMPS : 7.80 (+0.39%)
ATAI : 3.90 (+1.56%)
RVVTF : 0.3443 (+21.06%)
RVV.CN : 0.440 (+17.33%)
MNMD : 0.7986 (+3.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.3177
2nd Resistance Point 0.3089
1st Resistance Point 0.2966
Last Price 0.3443
1st Support Level 0.2755
2nd Support Level 0.2667
3rd Support Level 0.2544

See More

52-Week High 0.5100
Fibonacci 61.8% 0.3610
Last Price 0.3443
Fibonacci 50% 0.3150
Fibonacci 38.2% 0.2690
52-Week Low 0.1200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar